JPMorgan Predicts Boom in Obesity Drug Sales, Tipping Eli Lilly as Winner

JPMorgan forecasts a significant increase in direct-to-consumer sales for obesity drugs, identifying Eli Lilly as the primary beneficiary due to its 'best-in-class' GLP-1 status.